Market Place
Sourcing Support
AbbVie inks immune disorder drug licensing deal with China`s FutureGen
14 Jun 2024 //
REUTERS
TITAN-X A.I. Platform Validated through AbbVie’s Acquisition of Landos and NX-13
25 Mar 2024 //
BUSINESSWIRE
Landos Biopharma Provides Business Update and Reports Q4 and FY23 Results
21 Mar 2024 //
GLOBENEWSWIRE
Landos Biopharma to Present New Data on Immunometabolism
08 Jan 2024 //
GLOBENEWSWIRE
Landos Biopharma Publishes Results of NX-13 Phase 1b Study
21 Nov 2023 //
GLOBENEWSWIRE
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
09 Nov 2023 //
GLOBENEWSWIRE
Landos to Present at American College of Gastroenterology 2023 Annual Meeting
23 Oct 2023 //
GLOBENEWSWIRE
Landos to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis
19 Sep 2023 //
GLOBENEWSWIRE
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven
14 Sep 2023 //
GLOBENEWSWIRE
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
09 Aug 2023 //
GLOBENEWSWIRE
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Landos Biopharma Expands BOD with Appointment of Alka Batycky, Ph.D.
30 May 2023 //
GLOBENEWSWIRE
Landos Biopharma Announces 1-for-10 Reverse Stock Split
25 May 2023 //
GLOBENEWSWIRE
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
12 May 2023 //
GLOBENEWSWIRE
Landos Provides Business Update and Reports First Quarter 2023 Results
12 May 2023 //
GLOBENEWSWIRE
Landos Biopharma Provides Business Update and Reports
23 Mar 2023 //
GLOBENEWSWIRE
Landos Biopharma offloads former lead program to founder
01 Mar 2023 //
ENDPTS
Landos Announces Transfer of LANCL Portfolio, including Omilancor
28 Feb 2023 //
GLOBENEWSWIRE
Landos Announces Acceptance of Abstract on NX-13 Phase 1b Study in Colitis
11 Jan 2023 //
GLOBENEWSWIRE
Landos Biopharma Announces $16.7 Million Private Placement Financing
05 Jan 2023 //
GLOBENEWSWIRE
Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
05 Jan 2023 //
GLOBENEWSWIRE
Landos Biopharma Reports 2Q 2022 Results and Provides Business Update
11 Aug 2022 //
GLOBENEWSWIRE
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
03 Aug 2022 //
GLOBENEWSWIRE
Landos Names Gregory Oakes President and Chief Executive Officer
21 Jun 2022 //
GLOBENEWSWIRE
Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update
12 May 2022 //
GLOBENEWSWIRE
Landos Biopharma Reports Q4 and Full Year 2021 Results
24 Mar 2022 //
GLOBENEWSWIRE
Landos Biopharma Appoints Roger Adsett to its Board of Directors
10 Mar 2022 //
GLOBENEWSWIRE
Landos Biopharma Announces FDA Clearance of its IND for LABP-104
02 Nov 2021 //
BIOSPACE
Landos Announces First Subject Dosed in a Phase 1 Study of LABP-104
28 Oct 2021 //
GLOBENEWSWIRE
Landos Biopharma Announces FDA Clearance of its IND for LABP-104
11 Oct 2021 //
GLOBENEWSWIRE
Landos Biopharma Announces Publication in Scientific Reports Novel Preclinical
06 Oct 2021 //
GLOBENEWSWIRE
Landos to Participate in Truist Securities CEO Fireside Chat Series (Virtual)
27 Sep 2021 //
GLOBENEWSWIRE
Landos Biopharma to Collaborate with the Icahn School of Medicine at Mount Sinai
20 Sep 2021 //
GLOBENEWSWIRE
Landos to Present Results of LABP-104 in Lupus
15 Sep 2021 //
GLOBENEWSWIRE
Landos enters Research Collaboration into NLRX1 Pathway with Johns Hopkins
26 Aug 2021 //
GLOBENEWSWIRE
Landos Second Quarter 2021 Financial Results and Provides Business Updates
29 Jul 2021 //
GLOBENEWSWIRE
Landos Phase 2 Data of Omilancor in Ulcerative Colitisr Oral Presentation
22 Jul 2021 //
GLOBENEWSWIRE
Landos Phase 2 Data of Omilancor in Ulcerative Colitisr Oral Presentation
22 Jul 2021 //
GLOBENEWSWIRE
Landos Announces Positive Outcome of End-of-Ph2 Meeting with FDA for Omilancor
14 Jun 2021 //
GLOBENEWSWIRE
Landos Biopharma teams up with LianBio for $218M-plus collab
17 May 2021 //
FIERCE BIOTECH
Landos and LianBio Announce Exclusive Collaboration and License Agreement
17 May 2021 //
GLOBENEWSWIRE
Landos Biopharma and LianBio Announce Collaboration Omilancor and NX-13
17 May 2021 //
GLOBENEWSWIRE
Landos Biopharma Announces First Patient Dosed in a Phase 2 Study
06 May 2021 //
GLOBENEWSWIRE
AGTC Announces Data to be Presented from the Ongoing XLRP
29 Apr 2021 //
GLOBENEWSWIRE
Mirum and CANbridge Enter into Exclusive Licensing Agreement
29 Apr 2021 //
BUSINESSWIRE
Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13
29 Apr 2021 //
GLOBENEWSWIRE
Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic
26 Apr 2021 //
GLOBENEWSWIRE
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor
06 Apr 2021 //
GLOBENEWSWIRE
